Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study

Table 4 **LVEF decline* by prior treatment**

		n (%)
Prior treatment^†	n	Asymptomatic^‡	Symptomatic^‡	Total
None	19	5 (26)	0	5 (26)
Trastzumab only	4	0	0	0
Anthracycline only	11	5 (45)	1 (9)	6 (55)
Trastuzumab and anthracycline	26	8 (31)	5 (19)^§	13 (50)
All patients	60	18 (30)	6 (10)^¶	24 (40)

Abbreviations: AE adverse event, CTCAE Common Terminology Criteria for Adverse Events, LVEF left ventricular ejection fraction.
*Reported as an AE.
^†Trastuzumab and/or anthracycline.
^‡Asymptomatic, CTCAE grade 1/2; symptomatic, CTCAE grade 3/4.
^§One fatal event occurred (cardiogenic shock).
^¶Three of six of these patients discontinued the study due to LVEF decline.

ISSN: 1471-2407